1. Home
  2. CLLS vs TBI Comparison

CLLS vs TBI Comparison

Compare CLLS & TBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CLLS
  • TBI
  • Stock Information
  • Founded
  • CLLS 1999
  • TBI 1985
  • Country
  • CLLS France
  • TBI United States
  • Employees
  • CLLS N/A
  • TBI N/A
  • Industry
  • CLLS Biotechnology: Pharmaceutical Preparations
  • TBI Professional Services
  • Sector
  • CLLS Health Care
  • TBI Consumer Discretionary
  • Exchange
  • CLLS Nasdaq
  • TBI Nasdaq
  • Market Cap
  • CLLS 240.2M
  • TBI 223.4M
  • IPO Year
  • CLLS 2007
  • TBI 1996
  • Fundamental
  • Price
  • CLLS $1.97
  • TBI $7.34
  • Analyst Decision
  • CLLS Buy
  • TBI Buy
  • Analyst Count
  • CLLS 2
  • TBI 2
  • Target Price
  • CLLS $8.00
  • TBI $12.50
  • AVG Volume (30 Days)
  • CLLS 22.5K
  • TBI 236.4K
  • Earning Date
  • CLLS 11-04-2024
  • TBI 10-21-2024
  • Dividend Yield
  • CLLS N/A
  • TBI N/A
  • EPS Growth
  • CLLS N/A
  • TBI N/A
  • EPS
  • CLLS N/A
  • TBI N/A
  • Revenue
  • CLLS $19,635,000.00
  • TBI $1,764,450,000.00
  • Revenue This Year
  • CLLS $271.02
  • TBI N/A
  • Revenue Next Year
  • CLLS $33.48
  • TBI N/A
  • P/E Ratio
  • CLLS N/A
  • TBI N/A
  • Revenue Growth
  • CLLS N/A
  • TBI N/A
  • 52 Week Low
  • CLLS $0.96
  • TBI $7.09
  • 52 Week High
  • CLLS $3.77
  • TBI $16.14
  • Technical
  • Relative Strength Index (RSI)
  • CLLS 37.13
  • TBI 39.88
  • Support Level
  • CLLS $1.88
  • TBI $7.31
  • Resistance Level
  • CLLS $2.08
  • TBI $7.58
  • Average True Range (ATR)
  • CLLS 0.12
  • TBI 0.28
  • MACD
  • CLLS -0.04
  • TBI 0.00
  • Stochastic Oscillator
  • CLLS 17.31
  • TBI 3.75

About CLLS Cellectis S.A.

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.

About TBI TrueBlue Inc.

TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.

Share on Social Networks: